Navigation Links
Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
Date:6/8/2011

ed from the hospital within 48 hours after the surgical procedure.

The primary outcome measure was the difference in UPDRS motor scores between NLX-P101 and sham-treated subjects, when the subjects were off PD medication. Other tests assessed motor fluctuations, constancy of medication effect and neuropsychological evaluations. A clinically-meaningful response was defined based on a 25 percent mean improvement from the initial Phase 1 NLX-P101 study (9 points). Patients in the sham surgery arm of the study who continue to meet all eligibility requirements will be provided an opportunity to receive NLX-P101 in a planned cross-over study. Treated subjects continue to be evaluated in an open-label, long-term follow-up study.

A Novel Approach to Gene Therapy

NLX-P101 aims to reset the overactive brain cells in the STN to inhibit electrical activity and return brain network activity to more normal levels. In PD, the loss of dopamine-secreting neurons alters chemical signaling pathways in the brain such that input to the STN is altered. The therapeutic approach with NLX-P101 modulates the activity of the STN (which is overactive in PD) by restoring GABA, a neurotransmitter important in STN function. GABA is made by a gene called glutamic acid decarboxylase (GAD). NLX-P101 uses an AAV vector (a disabled, non-pathogenic virus) to deliver the GAD gene into the STN. Increasing GAD activity causes more GABA to be synthesized, thus helping to lessen the STN over-activity.

About Parkinson's disease

Parkinson's disease is a progressive and debilitating neurodegenerative disorder that arises from the gradual deterioration of nerve cells in the brain. It affects the control of bodily movement and is characterized by four principal features: limb tremor, limb rigidity, bradykinesia (slowness of movement) and postural instability (trouble with balance).  

Parkinson's disease is typically a disease that affects people over
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. Neurologix Reports Third Quarter 2010 Financial Results
4. Neurologix Completes Additional $7 Million Financing
5. Neurologix Announces First Quarter 2011 Financial Results
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... YORK and KISSING, Germany ... and distributor of a single use and computer-assisted ("robotic") ... (Homi) Shamir , a worldwide recognized medical device executive, ... Mr. Shamir is a highly respected global ... recent assignment he served as President and Chief Executive ...
(Date:7/30/2014)... and PARIS , July 30, ... ) and Sanofi (EURONEXT: SAN and NYSE: ... ODYSSEY trials of alirocumab in people with hypercholesterolemia met ... from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 ... an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin ...
(Date:7/30/2014)... -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a digital pathology ... and education markets, announced today that has been no ... disclosed or, to its knowledge, any other reason to ... "We have noticed unusual price and volume increases for ... Steve Barbee , CEO of DigiPath. "While we ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... 2011 Gamma Pharmaceuticals, Inc. (NASDAQ: GMPM.PK), a marketing ... through wholesalers and direct to retailers, both in the ... a sale and revenue collection cycle with a major ... products to a Northeast distribution center for delivery to ...
... Md., June 27, 2011 Glycotex, Inc., a ... has submitted the final results of the two ... product candidate, GLYC-101 gel, to the clinicaltrials.gov database. ... investigational GLYC-101 on wound closure in patients undergoing ...
Cached Medicine Technology:Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain 2Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain 3Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101 2Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101 3Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101 4
(Date:7/31/2014)... WA (PRWEB) July 31, 2014 ... family practice provider? Community Health Center of Snohomish ... “ Pediatricians vs. Family Doctors ”. Many adults ... are available to them. Community Health Center hopes ... similarities and differences between the two. , ...
(Date:7/31/2014)... The shale gas development that has vaulted ... U.S. natural gas production has raised concerns that local ... similar to previous resource extraction experiences in Pennsylvania’s history. ... & Jefferson College’s (W&J) Center for Energy Policy & ... that the gas boom in Pennsylvania is still underway, ...
(Date:7/31/2014)... OR (PRWEB) July 31, 2014 Sales in ... from 2013 to 2014, according to radio talk show host ... been experiencing rapid growth since 1990. The US economy in ... Kleyne Hour Power of Water radio show, reported this information ... Live Foods, a worldwide manufacturer of organic and natural food ...
(Date:7/31/2014)... 2014 According to new research ... Mycoprotein), by Type (Tofu, Tofu-Based Product, Tempeh, TVP, ... Global Trends & Forecasts to 2019", defines and ... analysis and forecasting of the market value of ... report also identifies the driving and restraining factors ...
(Date:7/31/2014)... 31, 2014 Care Communications, Inc., (CARE) ... firm, has received the Elite Award for “Recruitment, Selection ... one of twelve elite awards presented as part of ... Work For” 2014 awards competition. This marks the ... Award in the competition. CARE has also been chosen ...
Breaking Medicine News(10 mins):Health News:Community Health Center of Snohomish County Reveals the Differences Between Pediatricians and Family Practice Providers 2Health News:Pennsylvania’s Shale Gas: Examining the Boom and Bust Cycle 2Health News:Pennsylvania’s Shale Gas: Examining the Boom and Bust Cycle 3Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3Health News:Care Communications, Inc. Named an Elite Award Winner Among Top Chicago Employers 2
... , , HOFFMAN ESTATES, Ill., July 16 ... of America,s top medical institutions in the annual America,s Best Hospitals list ... magazine. St. Alexius Medical Center was ranked among the top 50 ... , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090716/CG47487 ...
... , , CARLSBAD, Calif., July 16 ... and microbial nucleic acid purification, announces the launch of an innovative ... genomic DNA from food cultured microorganisms. , , ... other commercial food kits with its easy-to-use protocol that allows for ...
... , , PALO ALTO, Calif., ... has been elected chairman of the company,s Board of Directors. , ... the biotechnology industry, and as the former chairman of Connetics Corporation ... leadership and success to TOPICA, as well as an exceptional knowledge ...
... , CHICAGO, July 16 Lexington Health ... services for those needing sub-acute medical and rehabilitative services as ... directors has named Dale Zaletel as the company,s new chief ... held the position of Chief Operating Officer since joining Lexington ...
... , Gamers Engage Memory, Attention, Processing Skills ... /PRNewswire-USNewswire/ -- The MS Technology Collaborative has created a ... brain power. The Collaborative, an alliance of Bayer HealthCare Pharmaceuticals, Microsoft, ... a free suite of online cognitive games for the MS community. ...
... , , , ... one of the nation,s leading domestic manufacturers of prescription foot ... awarded the prestigious Employer of the Year award, which is ... recognizes private sector employers that provide outstanding employment opportunities and ...
Cached Medicine News:Health News:St. Alexius Medical Center Named to America's Best Hospitals Rankings 2Health News:MO BIO Laboratories, Inc. Launches PowerFood(TM) Microbial DNA Isolation Kit 2Health News:TOPICA Elects G. Kirk Raab as Chairman of the Board 2Health News:Lexington Health Care Names New Chief Executive Officer 2Health News:Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 2Health News:Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 3Health News:Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 4Health News:PAL Health Technologies Wins State-Level Prestigious 'Employer of the Year' Award 2
... TruFit® CB Plugs use OBIs ... a scaffold for tissue repair that ... stable. A patented composite of ... the PolyGraft® material can be fabricated ...
The TruGraft BGS Granules are to be used in bone void filling of surgically or traumatically created osseous defects....
... the first to manufacture a diode pumped ... to announce their newest addition, the VITRA. ... the problem that many doctors face when ... No larger than a shoe box, this ...
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Medicine Products: